Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria Cohort A:~* ≥ 18 years old~* Employee of healthcare organization in South Dakota or Sanford Health employee in any location and with exposure to a person with COVID-19 within the last 5 days~  * Occupational exposure as determined by the participant's employee health department (i.e. not wearing the proper Personal Protective Equipment (PPE))~ * Criteria according to Center for Disease Control (CDC) guidelines~ * Community exposure (within 6 feet for at least 15 minutes)~* No current symptoms attributable to COVID-19, per HCW report (fever, cough, difficulty breathing, sore throat)~* No prior COVID-19 positive diagnosis (eligible if previous testing is negative and meets all other inclusion and exclusion)~* Ability to provide informed consent~Inclusion Criteria - Cohort B~* ≥ 18 years old~* High-risk person who had close contact (i.e. within 6 feet for at least 15 minutes) with a COVID-19 positive person within the last 5 days and is a South Dakota resident or high-risk person with close household contact of a COVID-19 positive Sanford employee~* High-risk person defined by:~* Age 18-44 with 2 or more comorbidities listed below~* Age 45-79 with any comorbid condition listed below~* Age 80 and above (regardless of comorbid conditions)~* Co-morbid list~  * Congestive Heart Failure (CHF)~ * Chronic lung disease (Includes any of the following: asthma, chronic obstructive pulmonary disease, emphysema)~ * Solid organ transplant or immunosuppression (Defined as an outpatient prescription of greater than 10 mg/day of prednisone or equivalent, use of chemotherapy, or use of immunosuppressive agents for solid organ transplant or for an autoimmune disease.)~ * Chronic Kidney Disease or End Stage Renal Disease~ * Diabetes mellitus~ * Cardiovascular disease/Hypertension~ * Smoking/Vaping (currently using or history of using in the past 1 year)~ * Obesity (calculated by height and weight per participant report)~ * Hyperlipidemia~* No current symptoms attributable to COVID-19~* No prior COVID-19 positive diagnosis (eligible if previous testing is negative and meets all other inclusion and exclusion)~* Ability to provide informed consent~* Confirmed review of concomitant medications (with emphasis on cardiac medications)~Exclusion Criteria Cohort A \& B:~* Known allergy to hydroxychloroquine or quinine~* Known history of long QT syndrome~* Known history of arrhythmia or dysrhythmia~* Known current QTc \>500 ms~* Known G6PD deficiency~* Known history of hypoglycemia~* Pregnant or Nursing by patient history~* Use of any of the following concomitant medications: See Appendix D for Exclusion medication list~* Concurrent diagnosis of dermatitis, porphyria, or psoriasis~* History of chronic liver disease, including cirrhosis and/or diagnosis of hepatitis (infectious, idiopathic, or immune)~* History of chronic kidney disease~* Pre-existing retinopathy~* Already taking hydroxychloroquine~* Any condition or medication in the opinion of the investigator that would prohibit the use of hydroxychloroquine~* Enrollment in another clinical with investigational drug or device~* Inability to swallow pills~* Adults unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cohort A: Healthcare worker (hydroxychloroquine) (Type: EXPERIMENTAL): None
- Cohort A: Healthcare worker (placebo) (Type: PLACEBO_COMPARATOR): None
- Cohort B: High-Risk participant (hydroxychloroqine) (Type: EXPERIMENTAL): None
- Cohort B: High-Risk participant (placebo) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy